Kanglong Huacheng (03759.HK) plans to invest about 2 billion yuan in Hangzhou Qiantang District to build a new drug commercial production and CDMO research and production service base.

The Zhitong Finance APP reported that Kanglong Huacheng (03759.HK) announced that, in order to further enhance the production capacity of commercialization of new drugs and R&D production services for CDMO, continuously strengthen the integrated service capabilities of new molecular type projects, consolidate the foundation of core business, comprehensively improve overall competitive strength and industry market position, the company intends to invest approximately RMB 2 billion to establish a new drug commercial production and CDMO R&D production service base (Hangzhou project) in Qiantang District, Hangzhou. On May 27, 2026, the company signed an "Investment Agreement" with the Hangzhou Qiantang District Investment Promotion Service Center regarding the Hangzhou project.